Literature DB >> 8613353

Dominance of conserved B-cell epitopes of the Plasmodium falciparum merozoite surface protein, MSP1, in blood-stage infections of naive Aotus monkeys.

G S Hui1, C Nikaido, C Hashiro, D C Kaslow, W E Collins.   

Abstract

We have shown that conserved B epitopes were immunodominant in animals hyperimmunized with parasite-purified or recombinant merozoite surface protein MSP1 of Plasmodium falciparum. Cross-priming studies also suggested that a conserved T-helper epitope(s) is efficient in inducing the anti-MSP1 antibody response. In this study, we determined whether a similar profile of immune responses was induced during live P. falciparum infections. Naive Aotus monkeys were infected by blood-stage challenge with either one of the two dimorphic MSP1 alleles represented by the FUP and FVO parasites. Sera collected after parasite clearance were analyzed by enzyme-linked immunosorbent assays (ELISAs). Monkeys infected with parasites carrying one allelic form of MSP1 had antibodies that were equally reactive with homologous or heterologous MSP1s. This preferential recognition of conserved epitopes of MSP1 was confirmed by competitive binding ELISAs. Studies with Plasmodium yoelii and P. falciparum show that the C-terminal 19-kDa fragment of MSP1, MSP1(19), is the target of protective immunity. Thus, monkey sera were assayed for recognition with recombinant MSP1(19)s expressing variant and conserved B epitopes. Results of direct and competitive binding ELISAs showed that the anti-MSP1(19) antibodies were also directed primarily against conserved determinants. The similarities between vaccine- or infection-induced antibody responses suggest a possible reciprocal enhancement of the two populations of anti-MSP1 antibodies when a subunit MSP1 vaccine is introduced into populations living in areas where malaria is endemic. This together with previous observations that conserved determinants are important in MSP1-mediated immunity provides an optimistic outlook that a subunit MSP1 vaccine may be effective and practical for field applications in malaria-exposed populations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8613353      PMCID: PMC173954          DOI: 10.1128/iai.64.5.1502-1509.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  31 in total

1.  Plasmodium falciparum: dimorphism of the p190 alleles.

Authors:  K Tanabe; K Murakami; S Doi
Journal:  Exp Parasitol       Date:  1989-05       Impact factor: 2.011

2.  Allelic dimorphism in a surface antigen gene of the malaria parasite Plasmodium falciparum.

Authors:  K Tanabe; M Mackay; M Goman; J G Scaife
Journal:  J Mol Biol       Date:  1987-05-20       Impact factor: 5.469

3.  The 3' portion of the gene for a Plasmodium yoelii merozoite surface antigen encodes the epitope recognized by a protective monoclonal antibody.

Authors:  J M Burns; T M Daly; A B Vaidya; C A Long
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

4.  Variation in the precursor to the major merozoite surface antigens of Plasmodium falciparum.

Authors:  M G Peterson; R L Coppel; P McIntyre; C J Langford; G Woodrow; G V Brown; R F Anders; D J Kemp
Journal:  Mol Biochem Parasitol       Date:  1988-01-15       Impact factor: 1.759

5.  A protective monoclonal antibody recognizes a variant-specific epitope in the precursor of the major merozoite surface antigen of the rodent malarial parasite Plasmodium yoelii.

Authors:  J M Burns; L A Parke; T M Daly; L A Cavacini; W P Weidanz; C A Long
Journal:  J Immunol       Date:  1989-04-15       Impact factor: 5.422

6.  Serum from Pf195 protected Aotus monkeys inhibit Plasmodium falciparum growth in vitro.

Authors:  G S Hui; W A Siddiqui
Journal:  Exp Parasitol       Date:  1987-12       Impact factor: 2.011

7.  Third form of the precursor to the major merozoite surface antigens of Plasmodium falciparum.

Authors:  M G Peterson; R L Coppel; M B Moloney; D J Kemp
Journal:  Mol Cell Biol       Date:  1988-06       Impact factor: 4.272

8.  A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria.

Authors:  S P Chang; S E Case; W L Gosnell; A Hashimoto; K J Kramer; L Q Tam; C Q Hashiro; C M Nikaido; H L Gibson; C T Lee-Ng; P J Barr; B T Yokota; G S Hut
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

9.  Immune response gene regulation of immunity to Plasmodium berghei sporozoites and circumsporozoite protein vaccines. Overcoming genetic restriction with whole organism and subunit vaccines.

Authors:  S L Hoffman; J A Berzofsky; D Isenbarger; E Zeltser; W R Majarian; M Gross; W R Ballou
Journal:  J Immunol       Date:  1989-05-15       Impact factor: 5.422

10.  The three major antigens on the surface of Plasmodium falciparum merozoites are derived from a single high molecular weight precursor.

Authors:  A A Holder; R R Freeman
Journal:  J Exp Med       Date:  1984-08-01       Impact factor: 14.307

View more
  10 in total

1.  In vivo expression and immunological studies of the 42-kilodalton carboxyl-terminal processing fragment of Plasmodium falciparum merozoite surface protein 1 in the baculovirus-silkworm system.

Authors:  Alan L Y Pang; Caryn N Hashimoto; Leslie Q Tam; Z Q Meng; George S N Hui; Walter K K Ho
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

2.  Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria.

Authors:  D Dodoo; T G Theander; J A Kurtzhals; K Koram; E Riley; B D Akanmori; F K Nkrumah; L Hviid
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  A Plasmodium vivax vaccine candidate displays limited allele polymorphism, which does not restrict recognition by antibodies.

Authors:  I S Soares; J W Barnwell; M U Ferreira; M Gomes Da Cunha; J P Laurino; B A Castilho; M M Rodrigues
Journal:  Mol Med       Date:  1999-07       Impact factor: 6.354

4.  Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial.

Authors:  A W Stowers; V Cioce; R L Shimp; M Lawson; G Hui; O Muratova; D C Kaslow; R Robinson; C A Long; L H Miller
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

5.  Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.

Authors:  Sanjay Singh; Kazutoyo Miura; Hong Zhou; Olga Muratova; Brian Keegan; Aaron Miles; Laura B Martin; Allan J Saul; Louis H Miller; Carole A Long
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

6.  Non-variant specific antibody responses to the C-terminal region of merozoite surface protein-1 of Plasmodium falciparum (PfMSP-1(19)) in Iranians exposed to unstable malaria transmission.

Authors:  Sedigheh Zakeri; Akram A Mehrizi; Samaneh Zoghi; Navid D Djadid
Journal:  Malar J       Date:  2010-09-16       Impact factor: 2.979

7.  Growth-inhibitory antibodies are not necessary for protective immunity to malaria infection.

Authors:  E Elsa Herdiana Murhandarwati; Lina Wang; Harini D de Silva; Charles Ma; Magdalena Plebanski; Casilda G Black; Ross L Coppel
Journal:  Infect Immun       Date:  2009-11-16       Impact factor: 3.441

8.  Immunogenicity of bacterial-expressed recombinant Plasmodium knowlesi merozoite surface protein-142 (MSP-142).

Authors:  Fei Wen Cheong; Mun Yik Fong; Yee Ling Lau; Rohela Mahmud
Journal:  Malar J       Date:  2013-12-19       Impact factor: 2.979

9.  The Plasmodium falciparum merozoite surface protein-1 19 KD antibody response in the Peruvian Amazon predominantly targets the non-allele specific, shared sites of this antigen.

Authors:  Patrick L Sutton; Eva H Clark; Claudia Silva; OraLee H Branch
Journal:  Malar J       Date:  2010-01-04       Impact factor: 2.979

10.  Antibody response dynamics to the Plasmodium falciparum conserved vaccine candidate antigen, merozoite surface protein-1 C-terminal 19kD (MSP1-19kD), in Peruvians exposed to hypoendemic malaria transmission.

Authors:  Katherine J Torres; Eva H Clark; Jean N Hernandez; Katherine E Soto-Cornejo; Dionicia Gamboa; OraLee H Branch
Journal:  Malar J       Date:  2008-09-09       Impact factor: 2.979

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.